Table 1.
Clinical and radiologic characteristics of patients with intermediate to advanced hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE) with or without H101
| Variable | Overall [cases (%)] | TACE group [cases (%)] | TACE with H101 group [cases (%)] | P value |
|---|---|---|---|---|
| Age (years) | 0.420 | |||
| ≤60 | 337 (70.8) | 164 (68.9) | 173 (72.7) | |
| >60 | 139 (29.2) | 74 (31.1) | 65 (27.3) | |
| Sex | 0.877 | |||
| Man | 430 (90.3) | 214 (89.9) | 216 (90.8) | |
| Woman | 46 (9.7) | 24 (10.1) | 22 (9.2) | |
| WBC (×109/L) | 0.693 | |||
| <10 | 449 (94.3) | 223 (93.7) | 226 (95.0) | |
| ≥10 | 27 (5.7) | 15 (6.7) | 12 (5.0) | |
| PLT (×109/L) | 0.123 | |||
| <100 | 58 (12.2) | 35 (14.7) | 23 (9.7) | |
| ≥100 | 418 (87.8) | 203 (85.3) | 215 (90.3) | |
| ALT (U/L) | 0.682 | |||
| <40 | 173 (36.3) | 79 (33.2) | 94 (39.5) | |
| ≥40 | 303 (63.7) | 159 (66.8) | 144 (60.5) | |
| AST (U/L) | 0.924 | |||
| <45 | 168 (35.3) | 83 (34.9) | 85 (35.7) | |
| ≥45 | 308 (64.7) | 155 (65.1) | 153 (64.3) | |
| ALB (g/L) | 0.417 | |||
| <35 | 63 (13.2) | 35 (14.7) | 28 (11.8) | |
| ≥35 | 413 (86.8) | 203 (85.3) | 210 (88.2) | |
| TBIL (mmol/L) | 0.066 | |||
| <20 | 381 (80.0) | 182 (76.5) | 199 (83.6) | |
| ≥20 | 95 (20.0) | 56 (23.5) | 39 (16.4) | |
| IBIL (mmol/L) | 0.011 | |||
| <15 | 431 (90.5) | 207 (87.0) | 224 (94.1) | |
| ≥15 | 45 (9.5) | 31 (13) | 14 (5.9) | |
| ALP (U/L) | 0.773 | |||
| <100 | 166 (34.9) | 81 (34.0) | 85 (35.7) | |
| ≥100 | 310 (65.1) | 157 (66.0) | 153 (64.2) | |
| CRP (mg/L) | 0.714 | |||
| <8.2 | 249 (52.3) | 127 (53.4) | 122 (51.2) | |
| ≥8.2 | 227 (47.7) | 111 (46.6) | 116 (48.8) | |
| AFP (ng/mL) | 0.923 | |||
| <25 | 164 (34.5) | 81 (34.0) | 83 (34.8) | |
| ≥25 | 312 (65.5) | 157 (66.0) | 155 (65.2) | |
| HBsAg | 0.046 | |||
| Negative | 27 (5.7) | 19 (8.0) | 8 (3.4) | |
| Positive | 449 (94.3) | 219 (92.0) | 230 (96.6) | |
| HBV-DNA (IU/mL) | 0.589 | |||
| <100 | 112 (23.5) | 59 (24.8) | 53 (22.2) | |
| ≥100 | 364 (76.5) | 179 (75.2) | 185 (77.8) | |
| NLR | 0.916 | |||
| <3 | 354 (74.4) | 178 (74.8) | 176 (73.9) | |
| ≥3 | 122 (25.6) | 60 (25.2) | 62 (26.1) | |
| Tumor size (cm) | 1.000 | |||
| <5 | 130 (27.3) | 65 (27.3) | 65 (27.3) | |
| ≥5 | 346 (72.7) | 173 (72.7) | 173 (72.7) | |
| Tumor number | 0.391 | |||
| Single | 172 (36.1) | 91 (38.2) | 81 (34.0) | |
| Multiple | 304 (63.9) | 147 (61.8) | 157 (66.0) | |
| Splenomegaly | 0.177 | |||
| No | 311 (65.3) | 148 (62.2) | 163 (68.5) | |
| Yes | 165 (34.7) | 90 (37.8) | 75 (31.5) | |
| Metastasis | 0.835 | |||
| No | 452 (95.0) | 227 (95.4) | 225 (94.5) | |
| Yes | 24 (5.0) | 11 (4.6) | 13 (5.5) | |
| Vascular invasion | 0.763 | |||
| No | 336 (70.6) | 170 (71.4) | 166 (69.7) | |
| Yes | 140 (29.4) | 68 (28.6) | 72 (30.3) | |
| Antiviral therapy | 0.066 | |||
| No | 251 (52.7) | 115 (48.3) | 136 (57.1) | |
| Yes | 225 (47.3) | 123 (51.7) | 102 (42.9) |
WBC white blood cell count, PLT platelet, ALT alanine transaminase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, IBIL indirect bilirubin, ALP alkaline phosphatase, CRP C-reactive protein, AFP alpha-fetoprotein, HBsAg surface antigen of hepatitis B virus, HBV hepatitis B virus, NLR neutrophil-to-lymphocyte ratio